DSK Legal Advised Tata Capital Healthcare Fund II In $20 Million Investment In Orbicular Pharmaceutical Technologies
DSK Legal has successfully assisted and advised Tata Capital Healthcare Fund II (TCHF-II), represented by its sole trustee
DSK Legal Advised Tata Capital Healthcare Fund II In $20 Million Investment In Orbicular Pharmaceutical Technologies
DSK Legal has successfully assisted and advised Tata Capital Healthcare Fund II (TCHF-II), represented by its sole trustee, Tata Trustee Company Private Limited, in a significant primary investment in Orbicular Pharmaceutical Technologies Private Limited (Orbicular).
TCHF-II, a healthcare-focused private equity fund of Tata Capital Limited, is registered with the Securities and Exchange Board of India (SEBI) under the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012. Orbicular is renowned for developing and manufacturing niche and complex generic finished dose pharmaceutical drug products across various therapeutic segments and dosage forms.
The scope of DSK Legal's work in the transaction included conducting comprehensive legal due diligence on Orbicular, and reviewing, revising, negotiating, and finalizing critical transaction documents such as the securities subscription agreement, shareholders agreement, and the promoter's employment agreement. Additionally, DSK Legal assisted in reviewing the conditions precedent and successfully undertaking the closing of the transaction.
The investment deal, valued at USD 20 million, was overseen by a proficient team from DSK Legal, comprising Mr. Mayank Mehta (Partner), Ms. Aishwarya Kapoor (Senior Associate), and Ms. Sonali Tiwari (Associate).